header-left
Share to Facebook Share to Twitter Bookmark and Share
File #: 180888    Version: Name:
Type: Bill Status: IN COUNCIL - SECOND READING
File created: 10/11/2018 In control: Committee on Public Health and Human Services
On agenda: Final action:
Title: Amending Title 6 of The Philadelphia Code, entitled "Health Code," by adding a new Chapter 6-1200, entitled "Pharmaceutical Sales and Marketing Practices," to provide for registration of pharmaceutical manufacturer agents and certain other requirements; and to prohibit gifts by pharmaceutical manufacturers and their agents to health care practitioners; all under certain terms and conditions.
Sponsors: Councilmember Greenlee, Councilmember Bass
Indexes: HEALTH CODE, PHARMACEUTICAL SALES AND MARKETING PRACTICES
Code sections: Title 6 - HEALTH CODE
Attachments: 1. Bill No. 18088801, As Amended.pdf
Date Ver.Action ByActionResultAction DetailsVideo
12/6/20181 CITY COUNCIL SUSPEND THE RULES OF THE COUNCILPass Action details Not available
12/6/20181 CITY COUNCIL ORDERED PLACED ON THIS DAY`S FIRST READING CALENDARPass Action details Not available
12/6/20181 CITY COUNCIL READ AND ORDERED PLACED ON NEXT WEEK'S SECOND READING CALENDAR  Action details Not available
11/30/20180 Committee on Public Health and Human Services HEARING NOTICES SENT  Action details Not available
11/30/20180 Committee on Public Health and Human Services HEARING HELD  Action details Not available
11/30/20180 Committee on Public Health and Human Services AMENDED  Action details Not available
11/30/20181 Committee on Public Health and Human Services REPORTED FAVORABLY, RULE SUSPENSION REQUESTED  Action details Not available
10/11/20180 CITY COUNCIL Introduced and ReferredPass Action details Not available
Title
Amending Title 6 of The Philadelphia Code, entitled "Health Code," by adding a new Chapter 6-1200, entitled "Pharmaceutical Sales and Marketing Practices," to provide for registration of pharmaceutical manufacturer agents and certain other requirements; and to prohibit gifts by pharmaceutical manufacturers and their agents to health care practitioners; all under certain terms and conditions.

Body
WHEREAS, the opioid crisis has reached epidemic proportions in Philadelphia, such that over 1,200 people are believed to have died from drug overdoses in 2017, over 80% of which involve prescription opioid painkillers, heroin, or fentanyl; and where tens of thousands of people are believed to be addicted to opioids; and

WHEREAS, four out of five new heroin users nationally started with prescription opioids; and

WHEREAS, rates of sales of prescription opioids more than doubled between 2001 and 2011 in Philadelphia and currently remain well above the sales levels of 2001; and

WHEREAS, this increase in sales has been driven to a significant extent by aggressive and misleading marketing by pharmaceutical companies and their representatives, who-as stated in detail in the complaint that the City has filed against multiple opioid manufacturers in City of Philadelphia v. Allergan, et al--encouraged health care providers to overprescribe these medications; and

WHEREAS, there is significant evidence that in-person sales visits by pharmaceutical representatives, accompanied by gifts such as free meals and office supplies, influence providers' prescribing behavior; and

WHEREAS, there is evidence that pharmaceutical companies have made misleading claims about medications other than opioids, such as Zyprexa, Effexor and Pamine; and

WHEREAS, prohibiting gifts of any value from pharmaceutical representatives to heath care providers will reduce inappropriate influence and restore trust among patients in their provi...

Click here for full text